Skip to content
2000
image of Efficacy and Safety of Ezetimibe for Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Abstract

Background and Aim

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world. It is associated with life-threatening conditions such as cardiovascular disease and hepatocellular carcinoma. This systematic review and meta-analysis aimed to evaluate ezetimibe in patients with NAFLD.

Methods

A comprehensive systematic search was conducted in PubMed, Scopus, Web of Science, and Cochrane CENTRAL up to August 8th, 2024, to identify relevant articles. The most used keywords for searching are “Ezetimibe” and “Nonalcoholic Fatty Liver Disease.” A random-effects model evaluated the standardized mean difference (SMD) and its 95% confidence interval (CI). All analyses were performed using the “meta” package in the R programming language version 4.3.1.

Results

Ten studies included in our study (five non-controlled and six controlled trials, with a total of 516 participants) investigated the effect of ezetimibe on different parameters. Ezetimibe significantly improves AST (SMD: -0.63, 95% CI: [-1.12, -0.14]), ALT (SMD: -0.50, 95% CI: [-0.91, -0.10]), GGT (SMD: -0.30, 95% CI: [-0.49, -0.10]), and LDL (SMD: -0.85, 95% CI: [-1.16, -0.54]), but was unable to improve HDL, TG, and BMI. Ezetimibe was also able to improve steatosis (SMD: -0.30, 95% CI: [-0.49, -0.10]), but inflammation (SMD: 0.06, 95% CI: [-0.57, 0.69]), ballooning (SMD: -0.62, 95% CI: [-1.55, 0.31]), and fibrosis (SMD: 0.03, 95% CI: [-0.25, 0.31]) were not improved.

Conclusion

Based on the findings, the administration of ezetimibe can reduce liver enzymes as well as the hepatic steatosis, but its effects on liver inflammation and fibrosis remain controversial. Further research is required to study its effects in combination with other treatments.

Prospero Registration Number

CRD4204609599.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crcep/10.2174/0127724328371387250606060831
2025-06-16
2025-09-29

  • From This Site

    /content/journals/crcep/10.2174/0127724328371387250606060831
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Choudhary N.S. Duseja A. Genetic and epigenetic disease modifiers: Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Transl. Gastroenterol. Hepatol. 2021 6 2 10.21037/tgh.2019.09.06 33409397
    [Google Scholar]
  2. Jarvis H. Craig D. Barker R. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020 17 4 e1003100 10.1371/journal.pmed.1003100 32353039
    [Google Scholar]
  3. Younossi Z.M. Marchesini G. Pinto-Cortez H. Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. Transplantation 2019 103 1 22 27 10.1097/TP.0000000000002484 30335697
    [Google Scholar]
  4. Yu Y. Cai J. She Z. Li H. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Adv. Sci. (Weinh.) 2019 6 4 1801585 10.1002/advs.201801585 30828530
    [Google Scholar]
  5. Arrese M. Arab J.P. Barrera F. Insights into nonalcoholic fatty-liver disease heterogeneity. Semin. Liver Dis. 2021 41 4 421 10.1055/s‑0041‑1730927
    [Google Scholar]
  6. Ko E. Yoon E.L. Jun D.W. Risk factors in nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2023 29 S79 S85 10.3350/cmh.2022.0398 36517003
    [Google Scholar]
  7. Ayonrinde O.T. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the past. JHEP Rep Innov Hepatol 2021 3 3 100261 10.1016/j.jhepr.2021.100261 34036255
    [Google Scholar]
  8. Radu F. Potcovaru C.G. Salmen T. Filip P.V. Pop C. Fierbințeanu-Braticievici C. The link between NAFLD and metabolic syndrome. Diagnostics 2023 13 4 614 10.3390/diagnostics13040614 36832102
    [Google Scholar]
  9. Zhu Z. Yang N. Fu H. Associations of lipid parameters with non-alcoholic fatty liver disease in type 2 diabetic patients according to obesity status and metabolic goal achievement. Front. Endocrinol. (Lausanne) 2022 13 1002099 10.3389/fendo.2022.1002099 36187115
    [Google Scholar]
  10. Godoy-Matos A.F. Silva J. ْJúniorWS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol. Metab. Syndr. 2020 12 1 60 10.1186/s13098‑020‑00570‑y 32684985
    [Google Scholar]
  11. Chalasani N. Younossi Z. Lavine J.E. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the study of liver diseases. Hepatology 2018 67 1 328 357 10.1002/hep.29367 28714183
    [Google Scholar]
  12. Ruan Z. Lu T. Chen Y. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol. 2022 158 7 745 753 10.1001/jamadermatol.2022.1609 35612851
    [Google Scholar]
  13. Hany M. Abouelnasr A.A. Abdelkhalek M.H. Effects of obstructive sleep apnea on non-alcoholic fatty liver disease in patients with obesity: A systematic review. Int. J. Obes. 2023 47 12 1200 1213 10.1038/s41366‑023‑01378‑2 37696927
    [Google Scholar]
  14. Francque S.M. Marchesini G. Kautz A. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep Innov Hepatol 2021 3 5 100322 10.1016/j.jhepr.2021.100322 34693236
    [Google Scholar]
  15. Heyens L.J.M. Busschots D. Koek G.H. Robaeys G. Francque S. Liver fibrosis in non-alcoholic fatty liver disease: From liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front. Med. (Lausanne) 2021 8 615978 10.3389/fmed.2021.615978 33937277
    [Google Scholar]
  16. Konyn P. Ahmed A. Kim D. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2023 29 S43 S57 10.3350/cmh.2022.0351 36417893
    [Google Scholar]
  17. Mantovani A. Csermely A. Petracca G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2021 6 11 903 913 10.1016/S2468‑1253(21)00308‑3 34555346
    [Google Scholar]
  18. Loomba R. Wong R. Fraysse J. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: A real world analysis of Medicare data. Aliment. Pharmacol. Ther. 2020 51 11 1149 1159 10.1111/apt.15679 32372515
    [Google Scholar]
  19. Loomba R. Friedman S.L. Shulman G.I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021 184 10 2537 2564 10.1016/j.cell.2021.04.015 33989548
    [Google Scholar]
  20. Huang D.Q. Terrault N.A. Tacke F. Global epidemiology of cirrhosis — aetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 2023 20 6 388 398 10.1038/s41575‑023‑00759‑2 36977794
    [Google Scholar]
  21. Bengtsson B. Stål P, Wahlin S, Björkström NK, Hagström H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int. 2019 39 6 1098 1108 10.1111/liv.14087 30829446
    [Google Scholar]
  22. Teng Y.X. Xie S. Guo P.P. Hepatocellular carcinoma in non-alcoholic fatty liver disease: Current progresses and challenges. J. Clin. Transl. Hepatol. 2022 10 5 955 964 10.14218/JCTH.2021.00586 36304509
    [Google Scholar]
  23. Pipitone R.M. Ciccioli C. Infantino G. MAFLD: A multisystem disease. Ther. Adv. Endocrinol. Metab. 2023 14 20420188221145549 10.1177/20420188221145549 36726391
    [Google Scholar]
  24. Kaya E. Yilmaz Y. Metabolic-associated Fatty Liver Disease (MAFLD): A multi-systemic disease beyond the liver. J. Clin. Transl. Hepatol. 2022 10 2 329 338 10.14218/JCTH.2021.00178 35528971
    [Google Scholar]
  25. Mantovani A. MAFLD vs NAFLD: Where are we? Dig. Liver Dis. 2021 53 10 1368 1372 10.1016/j.dld.2021.05.014 34108096
    [Google Scholar]
  26. Fouad Y. Elwakil R. Elsahhar M. The NAFLD‐MAFLD debate: Eminence vs evidence. Liver Int. 2021 41 2 255 260 10.1111/liv.14739 33220154
    [Google Scholar]
  27. García Compeán D Jiménez-Rodríguez AR. NAFLD vs MAFLD. The evidence-based debate has come. Time to change? Ann. Hepatol. 2022 27 6 100765 10.1016/j.aohep.2022.100765 36179795
    [Google Scholar]
  28. Paternostro R. Trauner M. Current treatment of non‐alcoholic fatty liver disease. J. Intern. Med. 2022 292 2 190 204 10.1111/joim.13531 35796150
    [Google Scholar]
  29. Moore M.P. Cunningham R.P. Dashek R.J. Mucinski J.M. Rector R.S. A fad too far? Dietary strategies for the prevention and treatment of NAFLD. Obesity (Silver Spring) 2020 28 10 1843 1852 10.1002/oby.22964 32893456
    [Google Scholar]
  30. Hallsworth K. Adams L.A. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep Innov Hepatol 2019 1 6 468 479 10.1016/j.jhepr.2019.10.008 32039399
    [Google Scholar]
  31. Gunta S.P. O’Keefe J.H. O’Keefe E.L. Lavie C.J. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients. Prog. Cardiovasc. Dis. 2023 79 12 18 10.1016/j.pcad.2023.02.007 36871887
    [Google Scholar]
  32. Jun B.G. Cheon G.J. The utility of ezetimibe therapy in nonalcoholic fatty liver disease. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.) 2019 34 2 284 285 10.3904/kjim.2019.043 30840809
    [Google Scholar]
  33. Nakade Y. Murotani K. Inoue T. Ezetimibe for the treatment of non‐alcoholic fatty liver disease: A meta‐analysis. Hepatol. Res. 2017 47 13 1417 1428 10.1111/hepr.12887 28257594
    [Google Scholar]
  34. Page M.J. McKenzie J.E. Bossuyt P.M. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 2021 88 105906 10.1016/j.ijsu.2021.105906 33789826
    [Google Scholar]
  35. Barker T.H. Stone J.C. Sears K. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth 2023 21 3 494 506 10.11124/JBIES‑22‑00430 36727247
    [Google Scholar]
  36. Barker T.H. Habibi N. Aromataris E. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth 2024 22 3 378 388 10.11124/JBIES‑23‑00268 38287725
    [Google Scholar]
  37. Takeshita Y. Takamura T. Honda M. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: A randomised controlled trial. Diabetologia 2014 57 5 878 890 10.1007/s00125‑013‑3149‑9 24407920
    [Google Scholar]
  38. Park H. Hasegawa G. Shima T. The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. Clin. Chim. Acta 2010 411 21-22 1735 1740 10.1016/j.cca.2010.07.012 20654606
    [Google Scholar]
  39. Yoneda M. Fujita K. Nozaki Y. Efficacy of ezetimibe for the treatment of non‐alcoholic steatohepatitis: An open‐label, pilot study. Hepatol. Res. 2010 40 6 566 573 10.1111/j.1872‑034X.2010.00644.x 20412324
    [Google Scholar]
  40. Shiwa T. Kawanami Y. Yokoyama T. Moritani A. Hashimoto M. Gotoh T. The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD). Nihon Shokakibyo Gakkai Zasshi 2011 108 8 1383 1392 21817841
    [Google Scholar]
  41. Enjoji M. Machida K. Kohjima M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis. 2010 9 1 29 10.1186/1476‑511X‑9‑29 20222991
    [Google Scholar]
  42. Ichimori S. Shimoda S. Goto R. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J. Diabetes Investig. 2012 3 2 179 184 10.1111/j.2040‑1124.2011.00147.x 24843563
    [Google Scholar]
  43. Cho Y. Rhee H. Kim Y. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (ESSENTIAL study). BMC Med. 2022 20 1 93 10.1186/s12916‑022‑02288‑2 35307033
    [Google Scholar]
  44. Noto D. Petta S. Giammanco A. Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial. Nutr. Metab. Cardiovasc. Dis. 2022 32 5 1288 1291 10.1016/j.numecd.2022.01.024 35256232
    [Google Scholar]
  45. Loomba R. Sirlin C.B. Ang B. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015 61 4 1239 1250 10.1002/hep.27647 25482832
    [Google Scholar]
  46. Hajiaghamohammadi A.A. A comparison of ezetimibe and acarbose in decreasing liver transaminase in nonalcoholic fatty liver disease: A randomized clinical trial. Govaresh 2013 18 3 186 190
    [Google Scholar]
  47. Sanal M.G. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J. Gastroenterol. 2015 21 11 3223 3231 10.3748/wjg.v21.i11.3223 25805928
    [Google Scholar]
  48. Hadizadeh F. Faghihimani E. Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J. Gastrointest. Pathophysiol. 2017 8 2 11 26 10.4291/wjgp.v8.i2.11 28573064
    [Google Scholar]
  49. Taylor R.S. Taylor R.J. Bayliss S. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology 2020 158 6 1611 1625.e12 10.1053/j.gastro.2020.01.043 32027911
    [Google Scholar]
  50. Ng C.H. Lim W.H. Hui Lim G.E. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2023 21 4 931 939.e5 10.1016/j.cgh.2022.04.014 35513235
    [Google Scholar]
  51. Miele L. Zocco M.A. Pizzolante F. Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. Metabolism 2020 112 154355 10.1016/j.metabol.2020.154355 32916154
    [Google Scholar]
  52. Brol M.J. Drebber U. Luetkens J.A. Odenthal M. Trebicka J. “The pathogenesis of hepatic fibrosis: Basic facts and clinical challenges”—assessment of liver fibrosis: a narrative review. Dig. Med. Res. 2022 5 24 10.21037/dmr‑22‑9
    [Google Scholar]
  53. Ratziu V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. J. Hepatol. 2018 68 2 353 361 10.1016/j.jhep.2017.12.001 29223369
    [Google Scholar]
  54. Katsiki N. Mikhailidis D.P. Mantzoros C.S. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016 65 8 1109 1123 10.1016/j.metabol.2016.05.003 27237577
    [Google Scholar]
  55. Roeb E. Non-alcoholic fatty liver diseases: Current challenges and future directions. Ann. Transl. Med. 2021 9 8 726 10.21037/atm‑20‑3760 33987424
    [Google Scholar]
  56. Shea S. Lionis C. Kite C. Challenges in the management of non-alcoholic fatty liver disease (NAFLD): Towards a compassionate approach. Livers 2023 3 3 434 447 10.3390/livers3030031
    [Google Scholar]
  57. Fernلndez T Viñuela M, Vidal C, Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One 2022 17 2 e0263931 10.1371/journal.pone.0263931 35176096
    [Google Scholar]
  58. Younossi Z.M. Corey K.E. Lim J.K. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology 2021 160 3 912 918 10.1053/j.gastro.2020.11.051 33307021
    [Google Scholar]
  59. Koutoukidis D.A. Koshiaris C. Henry J.A. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2021 115 154455 10.1016/j.metabol.2020.154455 33259835
    [Google Scholar]
  60. Yang H. Suh D.H. Jung E.S. Ezetimibe, Niemann-Pick C1 like 1 inhibitor, modulates hepatic phospholipid metabolism to alleviate fat accumulation. Front. Pharmacol. 2024 15 1406493 10.3389/fphar.2024.1406493 38953111
    [Google Scholar]
  61. Pradhan A. Bhandari M. Sethi R. Ezetimibe and improving cardiovascular outcomes: Current evidence and perspectives. Cardiol. Res. Pract. 2020 2020 9815016 10.1155/2020/9815016
    [Google Scholar]
  62. Lee H.Y. Jun D.W. Kim H.J. Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.) 2019 34 2 296 304 10.3904/kjim.2017.194 29551054
    [Google Scholar]
  63. Sanyal D. Mukherjee P. Raychaudhuri M. Ghosh S. Mukherjee S. Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J. Endocrinol. Metab. 2015 19 5 597 601 10.4103/2230‑8210.163172 26425466
    [Google Scholar]
  64. Gîlcă-Blanariu G.E. Budur D.S. Mitrică D.E. Advances in noninvasive biomarkers for nonalcoholic fatty liver disease. Metabolites 2023 13 11 1115 10.3390/metabo13111115 37999211
    [Google Scholar]
  65. Ekstedt M. Franzén L.E. Mathiesen U.L. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†. Hepatology 2006 44 4 865 873 10.1002/hep.21327 17006923
    [Google Scholar]
  66. Westfall E. Jeske R. Bader A.R. Nonalcoholic fatty liver disease: Common Questions and answers on diagnosis and management. Am. Fam. Physician 2020 102 10 603 612 33179890
    [Google Scholar]
  67. Thakur S. Kumar V. Das R. Sharma V. Mehta D.K. Biomarkers of hepatic toxicity: An overview. Curr. Ther. Res. Clin. Exp. 2024 100 100737 10.1016/j.curtheres.2024.100737 38860148
    [Google Scholar]
  68. Abel T. Fehér J. Dinya E. Eldin M.G. Kov ács A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med. Sci. Monit. 2009 15 12 MS6 MS11 19946244
    [Google Scholar]
  69. Biberci Keskin E. Çoban G. Evaluation of liver biopsy findings and comparison with noninvasive fibrosis scores in patients with non-alcoholic steatohepatitis. Medeniyet Med J 2019 34 4 354 359 10.5222/MMJ.2019.48640 32821461
    [Google Scholar]
  70. Brunt E.M. Kleiner D.E. Carpenter D.H. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology 2021 73 5 2028 2038 10.1002/hep.31599 33111374
    [Google Scholar]
  71. Li Y.Y. Zheng T.L. Xiao S.Y. Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions. Liver Int. 2023 43 6 1170 1182 10.1111/liv.15571 37017559
    [Google Scholar]
  72. Chowdhury A.B. Mehta K.J. Liver biopsy for assessment of chronic liver diseases: A synopsis. Clin. Exp. Med. 2022 23 2 273 285 10.1007/s10238‑022‑00799‑z 35192111
    [Google Scholar]
  73. Jang W. Song J.S. Non-invasive imaging methods to evaluate non-alcoholic fatty liver disease with fat quantification: A review. Diagnostics 2023 13 11 1852 10.3390/diagnostics13111852 37296703
    [Google Scholar]
  74. Chartampilas E. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones (Athens) 2018 17 1 69 81 10.1007/s42000‑018‑0012‑x 29858854
    [Google Scholar]
  75. Xu Q. Feng M. Ren Y. From NAFLD to HCC: Advances in noninvasive diagnosis. Biomed. Pharmacother. 2023 165 115028 10.1016/j.biopha.2023.115028 37331252
    [Google Scholar]
  76. Caussy C. Reeder S.B. Sirlin C.B. Loomba R. Noninvasive, quantitative assessment of liver fat by MRI‐PDFF as an endpoint in NASH trials. Hepatology 2018 68 2 763 772 10.1002/hep.29797 29356032
    [Google Scholar]
  77. Stine J.G. Munaganuru N. Barnard N. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2021 19 11 2274 10.1016/j.cgh.2020.08.061
    [Google Scholar]
  78. Selvaraj EA Mózes FE Jayaswal ANA Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J. Hepatol. 2021 75 4 770 785 10.1016/j.jhep.2021.04.044 33991635
    [Google Scholar]
  79. Meyer T. Castelein J. Schattenfroh J. Magnetic resonance elastography in a nutshell: Tomographic imaging of soft tissue viscoelasticity for detecting and staging disease with a focus on inflammation. Prog. Nucl. Magn. Reson. Spectrosc. 2024 144-145 1 14 10.1016/j.pnmrs.2024.05.002 39645347
    [Google Scholar]
  80. Pepin K.M. Welle C.L. Guglielmo F.F. Dillman J.R. Venkatesh S.K. Magnetic resonance elastography of the liver: everything you need to know to get started. Abdom. Radiol. (N.Y.) 2022 47 1 94 114 10.1007/s00261‑021‑03324‑0 34725719
    [Google Scholar]
  81. Demirtaş D. Ünal E. İdilman İ.S. Magnetic resonance elastography in evaluation of liver fibrosis in children with chronic liver disease. Insights Imaging 2023 14 1 39 10.1186/s13244‑023‑01390‑0 36854936
    [Google Scholar]
/content/journals/crcep/10.2174/0127724328371387250606060831
Loading
Efficacy and Safety of Ezetimibe for Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0127724328371387250606060831
/content/journals/crcep/10.2174/0127724328371387250606060831
/content/journals/crcep/10.2174/0127724328371387250606060831
Loading

Data & Media loading...

Supplements

PRISMA Checklist and Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: liver cirrhosis ; metabolic-dysfunction associated fatty liver disease ; non-alcoholic steatohepatitis ; non-alcoholic fatty liver disease ; Ezetimibe ; liver inflammation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test